Qiagen to acquire STAT-Dx

Germany-headquartered Qiagen (Nasdaq: QGEN) has entered into an agreement to acquire STAT-Dx, a privately-held Spanish company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven Qiagen chemistries.

The system, to be branded as QIAstat-Dx subject to closing of the transaction that is planned for the second quarter of 2018, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously to diagnose syndromes such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights in about one hour into the precise cause of various syndromes. Qiagen believes this proprietary system has the capabilities to help drive greater dissemination of molecular testing.

Transaction summary